PopVax's Cutting-Edge mRNA COVID-19 Vaccine Joins U.S. Project NextGen

PopVax, an Indian biotechnology firm specializing in mRNA vaccines, has been selected for the U.S. Government’s Project NextGen. The initiative, led by the NIH’s NIAID, will conduct a Phase I trial of PopVax’s COVID-19 vaccine, which demonstrated superior antibody responses in mice. The trial starts in 2025.

In a significant development for global health, PopVax, an innovative biotechnology company based in India, has been included in the U.S. Government's Project NextGen. The project aims to advance leading-edge vaccines and therapeutics against public health threats.

PopVax's novel mRNA COVID-19 vaccine has been chosen for its promising results in preliminary studies, where it elicited significantly stronger immune responses compared to current vaccines. The National Institute of Allergy and Infectious Diseases will oversee a Phase I trial in the United States, set to commence in early 2025.

PopVax employs machine learning to design proteins and uses cutting-edge delivery systems, showcasing India's growing prowess in biotechnology. Their work, supported by the Bill & Melinda Gates Foundation and others, represents a leap forward in vaccine development, with multiple candidates heading for trials.

(With inputs from agencies.)